tetano
Editor, Senior Moderator
Diagnostics (Basel)
. 2021 Dec 30;12(1):85.
doi: 10.3390/diagnostics12010085.
Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer
Seri Jeong[SUP] 1 [/SUP], Nuri Lee[SUP] 1 [/SUP], Su-Kyung Lee[SUP] 2 [/SUP], Eun-Jung Cho[SUP] 2 [/SUP], Jungwon Hyun[SUP] 2 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP], Eun-Ju Jung[SUP] 3 [/SUP], Heungjeong Woo[SUP] 3 [/SUP], Yu-Bin Seo[SUP] 4 [/SUP], Jin-Ju Park[SUP] 4 [/SUP], Hyun-Soo Kim[SUP] 2 [/SUP]
Affiliations
Abstract
We investigated the longevity rates of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after a complete ChAdOx1 nCoV-19 vaccination, which are rare and important to estimate their efficacy and establish a vaccination strategy. We assessed the positivity rates and changes of titers before (T0) and at one month (T1), four months (T2), and seven months (T3) after a ChAdOx1 nCoV-19 vaccination using five SARS-CoV-2 antibody assays. A total of 874 serum samples were obtained from 228 (T0 and T1), 218 (T2), and 200 (T3) healthcare workers. The positive rates for all five assays were 0.0-0.9% at T0, 66.2-92.5% at T1, 98.2-100.0% at T2, and 66.0-100.0% at T3. The positive rates at T3 were decreased compared to those at T2. The median antibody titers of all the assays at T3 were significantly decreased compared to those at T2 (860.5 to 232.0 U/mL for Roche total, 1041.5 to 325.5 AU/mL for Abbott IgG, 10.9 to 2.3 index for Siemens IgG, 99.5% to 94.7% for SD Biosensor V1, and 88.5% to 38.2% for GenScript). A third-dose scheme can be considered based on our data generated from five representative assays. Our findings contribute insights into SARS-CoV-2 antibody assays and appropriate vaccination strategies.
Keywords: ChAdOx1 nCoV-19; SARS-CoV-2; antibodies; assay; vaccine; viral load.
. 2021 Dec 30;12(1):85.
doi: 10.3390/diagnostics12010085.
Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer
Seri Jeong[SUP] 1 [/SUP], Nuri Lee[SUP] 1 [/SUP], Su-Kyung Lee[SUP] 2 [/SUP], Eun-Jung Cho[SUP] 2 [/SUP], Jungwon Hyun[SUP] 2 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP], Eun-Ju Jung[SUP] 3 [/SUP], Heungjeong Woo[SUP] 3 [/SUP], Yu-Bin Seo[SUP] 4 [/SUP], Jin-Ju Park[SUP] 4 [/SUP], Hyun-Soo Kim[SUP] 2 [/SUP]
Affiliations
- PMID: 35054251
- DOI: 10.3390/diagnostics12010085
Abstract
We investigated the longevity rates of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after a complete ChAdOx1 nCoV-19 vaccination, which are rare and important to estimate their efficacy and establish a vaccination strategy. We assessed the positivity rates and changes of titers before (T0) and at one month (T1), four months (T2), and seven months (T3) after a ChAdOx1 nCoV-19 vaccination using five SARS-CoV-2 antibody assays. A total of 874 serum samples were obtained from 228 (T0 and T1), 218 (T2), and 200 (T3) healthcare workers. The positive rates for all five assays were 0.0-0.9% at T0, 66.2-92.5% at T1, 98.2-100.0% at T2, and 66.0-100.0% at T3. The positive rates at T3 were decreased compared to those at T2. The median antibody titers of all the assays at T3 were significantly decreased compared to those at T2 (860.5 to 232.0 U/mL for Roche total, 1041.5 to 325.5 AU/mL for Abbott IgG, 10.9 to 2.3 index for Siemens IgG, 99.5% to 94.7% for SD Biosensor V1, and 88.5% to 38.2% for GenScript). A third-dose scheme can be considered based on our data generated from five representative assays. Our findings contribute insights into SARS-CoV-2 antibody assays and appropriate vaccination strategies.
Keywords: ChAdOx1 nCoV-19; SARS-CoV-2; antibodies; assay; vaccine; viral load.